Tokyo (JCN) - Wyeth Japan announced on July 25 that it has obtained approval for Mylotarg, a proprietary preparation of gemtuzumab ozogamicin, from the Ministry of Health, Labor and Welfare. Mylotarg is a calicheamicin-conjugated humanized anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). AML is the most frequent leukemia in adults.
